<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947268</url>
  </required_header>
  <id_info>
    <org_study_id>SHARON PELVIS (phase II trial)</org_study_id>
    <nct_id>NCT03947268</nct_id>
  </id_info>
  <brief_title>Radiotherapy in Palliation of Advanced Pelvic Cancer</brief_title>
  <official_title>Palliative Short-course Radiotherapy in Advanced Pelvic Cancer: a Phase II Study (SHARON Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study wants to define the safety and efficacy of a short-course radiation therapy in
      patients with symptomatic advanced pelvic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      he study wants to define the safety and efficacy of a short course accelerated radiation
      therapy delivered in twice daily fractions and 2 consecutive days for symptomatic palliation
      of advanced solid cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2009</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of symptoms [pain]</measure>
    <time_frame>1 year]</time_frame>
    <description>Pain after treatment is evaluated with the Visual Analogic scale (VAS). Values range from 0 (no pain) to 10 (maximum possible pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Acute radiation toxicity]</measure>
    <time_frame>1 year</time_frame>
    <description>Acute toxicity after treatment is evaluated with the Common Terminology Criteria for Adverse Events (CTCAE). Values range from 1 (minimum acute toxicity) to 5 (maximum acute toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Late radiation toxicity]</measure>
    <time_frame>1 year</time_frame>
    <description>Late toxicity after the treatment is evaluated with the Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC). Values range from 1 (minimum late toxicity) to 5 (maximum/severe late toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Quality of life (QOL)</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life after the treatment is evaluated according with the Cancer Linear Analog Scale (CLAS). CLAS scale evaluates well-being, fatigue, and ability to perform daily activities. This method is based on a linear analogue scale. Values range from 0 (better status) to 10 (worst status).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Short-course radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course radiotherapy</intervention_name>
    <description>An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.</description>
    <arm_group_label>Short-course radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven advanced pelvic cancer

          -  excluded from curative therapy because of disease stage and/or presence of multiple
             comorbidities and/or poor performance status

          -  age &gt; 18 years

          -  Eastern Cooperative Oncology Group (ECOG) &lt;3

        Exclusion Criteria:

        - prior radiotherapy to the same region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G. Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>palliative care</keyword>
  <keyword>pelvic cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>pain</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

